These tutorials will provide an overview of the monitoring strategies for patients at risk of cardiomyopathy as a consequence of cancer therapy. Algorithms for monitoring patients who are actively receiving anthracyclines or trastuzumab therapy will be reviewed as well as the surveillance of survivors following exposure to these medications or radiation therapy. They will provide an overview of the main treatment strategies for patients who developed cardiomyopathy as a consequence of cancer therapy. Data from clinical studies and trials will be reviewed and pragmatic management plans will be presented. Furthermore, reflecting on cardiotoxicity risk prediction models and evidence-based modes of prevention of cancer therapy-induced cardiomyopathy. They will provide an overview of the emerging field of Cardio-Oncology and associated cardiotoxicity. The AHA/ACC Heart Failure Guidelines define individuals with exposure to cardiotoxic medications, as ‘at risk’ for heart failure, or Stage A. An understanding of the types of oncologic treatments and the pathophysiological mechanisms that are associated with cardiotoxicity provides the foundation for optimal cardiovascular care and surveillance of patients receiving cardiotoxic agents.